Entrada Therapeutics (TRDA) Depreciation and Depletion (2020 - 2026)

Entrada Therapeutics' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $800000.0 for Q1 2026.

• On a quarterly basis, Depreciation and Depletion fell 11.11% year-over-year to $800000.0 in Q1 2026; TTM through Mar 2026 was $4.0 million, a 7.45% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 7.79% from the prior year.
• Depreciation and Depletion eased to $800000.0 in Q1 2026 per TRDA's latest filing, from $896000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $1.2 million in Q3 2025 and bottomed at $390000.0 in Q1 2022.
• The 5-year median for Depreciation and Depletion is $800000.0 (2023), against an average of $782705.9.
• Across the five-year window, Depreciation and Depletion soared 95.0% in 2022 and dropped 12.07% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $526000.0 in 2022, then jumped by 33.08% to $700000.0 in 2023, then surged by 45.57% to $1.0 million in 2024, then fell by 12.07% to $896000.0 in 2025, then fell by 10.71% to $800000.0 in 2026.
• Per Business Quant, the three latest TRDA Depreciation and Depletion figures stand at $800000.0 (Q1 2026), $896000.0 (Q4 2025), and $1.2 million (Q3 2025).